Despite widespread clinical use of antimalarial drugs such as hydroxychloroquine and
chloroquine in the treatment of rheumatoid arthritis (RA), systemic lupus erythematosus …

The heterogeneity of systemic lupus erythematosus (SLE), long recognised by clinicians, is
now challenging the entire lupus community, from geneticists to clinical investigators …

Besides treating acute flares, the management of SLE should aim at preventing organ
damage accrual and drug-associated harms, improving health-related quality of life and …

The current treatment approach for systemic lupus erythematosus (SLE), as outlined in the
recommendations by international medical associations including EULAR and the ACR, is …

Objective In 2016, the American Academy of Ophthalmology (AAO) changed the
recommended daily dose of hydroxychloroquine (HCQ) from 6.5 mg/kg to< 5 mg/kg …

The last decade has witnessed rapid growth in awareness of the rheumatic diseases of
childhood, an enhanced understanding of many of the unique aspects of their presentation …

Objectives To assess the associations of severe non‐adherence to HCQ, objectively
assessed by HCQ serum levels, and risks of SLE flares, damage, and mortality over 5 years …

Systemic lupus erythematosus (SLE) is an immune-mediated multi-systemic disease
characterized by a wide variability of clinical manifestations and a course frequently subject …

Objective Recent data show that lower hydroxychloroquine (HCQ) doses are associated
with a two‐to six‐fold higher risk of lupus flares. Thus, establishing an effective reference …

Objective The goals of this study were to assess the associations of severe nonadherence to
hydroxychloroquine (HCQ), objectively assessed by HCQ serum levels, and risks of …